

Assessment of Risk for USP <800> Compliant Alternative Containment Strategy

Drug Name: Mycophenolate	Assessment of Risk Completed on (Date): 7/28/19
Type of HD <ul style="list-style-type: none">• Non-antineoplastic (may pose a reproductive risk)	
Dosage Form <ul style="list-style-type: none">• Tablet of conventionally manufactured product that requires only packaging or counting• Liquid of conventionally manufactured product that requires only labeling or pouring• Capsule of conventionally manufactured product that requires only packaging or counting	
Pregnancy Category: D	
Risk of Exposure <ul style="list-style-type: none">• NIOSH Table 2: The drug meets one or more of the NIOSH criteria for a hazardous drug. Some of these drugs may represent an occupational hazard to males or females who are actively trying to conceive, women who are pregnant or may become pregnant, and women who are breast-feeding, because they may be present in breast milk. Supplemental Information: Route of exposure: Contact with skin (injectables, repackaged oral liquids) Ingestion of HD materials (capsules) Inhalation (powder)	
Containment Strategies <ul style="list-style-type: none">• All HD drugs, except for an antineoplastic, will be handled and stored per the manufacturer• Staff who are pregnant, of childbearing age, or trying to conceive should wear appropriate PPE when handling/dispensing HD medications• When cleaning any device, equipment, counting tray that comes in contact with a HD, a single glove must be used• Counting or repackaging of HDs must be done carefully. Clean equipment should be dedicated for use with HDs and should be decontaminated after every use.• Student Health Pharmacy does not cut, crush, or otherwise manipulate medications before dispensing to the patient.• Staff must avoid inhalation or direct contact with skin or mucous membranes if reconstituting oral suspension or if exposed to powder contained in capsule. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.	
Based on Assessment of Risk our pharmacy will proceed as follows: <ul style="list-style-type: none">• Follow containment strategies documented above and in SHS Hazardous Drugs Policy & Procedures• Follow USP <800> recommendations	

Reviewed by Pharmacy Manager:

Date: _____